Can Charles Schwab Stock Double?
Charles Schwab (NYSE:SCHW) needs no introduction as a goliath in…
Sell
49
TECX Quote, Financials, Valuation and Earnings
Last price:
$46.56
Seasonality move
:
-9.06%
Day range:
$40.28 - $47.50
52-week range:
$12.12 - $53.41
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.59x
Volume:
410.5K
Avg. volume:
120.5K
1-year change:
192.86%
Market cap:
$689.5M
Revenue:
--
EPS (TTM):
-$3.45
Analysts' Opinion
-
Consensus RatingTectonic Therapeutic has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $74.67, Tectonic Therapeutic has an estimated upside of 59.75% from its current price of $46.74.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $69.00 representing 100% downside risk from its current price of $46.74.
Fair Value
-
According to the consensus of 3 analysts, Tectonic Therapeutic has 59.75% upside to fair value with a price target of $74.67 per share.
TECX vs. S&P 500
-
Over the past 5 trading days, Tectonic Therapeutic has overperformed the S&P 500 by 9.33% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Tectonic Therapeutic does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Tectonic Therapeutic has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Tectonic Therapeutic reported revenues of --.
Earnings Growth
-
Tectonic Therapeutic has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Tectonic Therapeutic reported earnings per share of -$1.20.
Enterprise value:
530.4M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-4.61x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -$51.8M | -$10.1M | -$19.6M | |
| EBITDA | -- | -- | -$50M | -$9.6M | -$17.3M | |
| Diluted EPS | -- | -- | -$3.45 | -$0.68 | -$1.20 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | $7.3M | $162.6M | |
| Total Assets | -- | -- | -- | $15.8M | $168.7M | |
| Current Liabilities | -- | -- | -- | $12M | $17.3M | |
| Total Liabilities | -- | -- | -- | $95.6M | $18.4M | |
| Total Equity | -- | -- | -- | -$79.8M | $150.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -$114.5M | -$29M | -$42.3M | |
| Cash From Investing | -- | -- | -$604K | -$229K | -$153K | |
| Cash From Financing | -- | -- | $351.2M | -$383K | $172.8M | |
| Free Cash Flow | -- | -- | -$115.1M | -$29.3M | -$42.4M | |
TECX
Sector
Market Cap
$689.5M
$45.7M
Price % of 52-Week High
87.51%
47.99%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.78%
1-Year Price Total Return
192.86%
-31.8%
Beta (5-Year)
1.175
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$41.80
200-day SMA
Buy
Level
$27.19
Bollinger Bands (100)
Buy
Level
27.49 - 48.41
Chaikin Money Flow
Sell
Level
-35.4M
20-day SMA
Buy
Level
$44.36
Relative Strength Index (RSI14)
Buy
Level
56.40
ADX Line
Buy
Level
12.91
Williams %R
Neutral
Level
-25.7296
50-day SMA
Buy
Level
$45.84
MACD (12, 26)
Sell
Level
-0.94
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
108.4M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease.
Stock Forecast FAQ
In the current month, TECX has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TECX average analyst price target in the past 3 months is $74.67.
-
Where Will Tectonic Therapeutic Stock Be In 1 Year?
According to analysts, the consensus estimate is that Tectonic Therapeutic share price will rise to $74.67 per share over the next 12 months.
-
What Do Analysts Say About Tectonic Therapeutic?
Analysts are divided on their view about Tectonic Therapeutic share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Tectonic Therapeutic is a Sell and believe this share price will drop from its current level to $69.00.
-
What Is Tectonic Therapeutic's Price Target?
The price target for Tectonic Therapeutic over the next 1-year time period is forecast to be $74.67 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TECX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Tectonic Therapeutic is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TECX?
You can purchase shares of Tectonic Therapeutic via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Tectonic Therapeutic shares.
-
What Is The Tectonic Therapeutic Share Price Today?
Tectonic Therapeutic was last trading at $46.56 per share. This represents the most recent stock quote for Tectonic Therapeutic. Yesterday, Tectonic Therapeutic closed at $46.74 per share.
-
How To Buy Tectonic Therapeutic Stock Online?
In order to purchase Tectonic Therapeutic stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Stanley Druckenmiller Buy Teva Stock?
Billionaire Stanley Druckenmiller has been shaking up his portfolio lately,…
Why Did Stanley Druckenmiller Buy Philip Morris?
If you only look at consumer trends within the United…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 120x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 38x
Alerts
Buy
75
EXOD alert for Jan 25
Exodus Movement [EXOD] is up 37.5% over the past day.
Buy
61
TWLO alert for Jan 25
Twilio [TWLO] is up 20.12% over the past day.
Buy
75
HZO alert for Jan 25
MarineMax [HZO] is down 4.7% over the past day.
